EVERSANA strengthens global market access and pricing leadership in European expansion
CHICAGO, May 6, 2021 /PRNewswire/ EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, today announced key appointments across Europe to further strengthen its worldwide market access and pricing solutions leadership position. Building on our industry-leading global pricing data and software solutions, we ve recruited widely recognized experts who not only understand market access complexities across Europe but will strategically assess and deploy the solutions needed for clients either entering the European markets, expanding their country-to-country access or ready to commercialise worldwide, said Jim Lang, CEO, EVERSANA. With additional European expertise, EVERSANA is uniquely positioned to activate niche engagements or full-scale commercial services in and outside the region.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
EVERSANA™ strengthens global market access and pricing leadership in European expansion
May 6, 2021 GMT
EVERSANA logo (PRNewsfoto/EVERSANA)
CHICAGO, May 6, 2021 /PRNewswire/ EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today announced key appointments across Europe to further strengthen its worldwide market access and pricing solutions leadership position.
“Building on our industry-leading global pricing data and software solutions, we’ve recruited widely recognized experts who not only understand market access complexities across Europe but will strategically assess and deploy the solutions needed for clients either entering the European markets, expanding their country-to-country access or ready to commercialise worldwide,” said Jim Lang, CEO, EVERSANA. “With additional European expertise, EVERSANA is uniquely position
Share this article
Share this article
CHICAGO, Feb. 25, 2021 /PRNewswire/ EVERSANA™, the pioneer of next-generation commercial services to the global life sciences industry, today unveiled its comprehensive data, technology and services solution to bring the power of real-world data to chronic disease research, evidence generation and patient support. Through the ACTICS by EVERSANA technology platform, paired with robust outsourced service capabilities in value and evidence research and patient hub services, EVERSANA s Chronic Disease Real-World Data (RWD) solution enables life sciences stakeholders to conduct regulatory-grade research studies, generate evidence and provide data-driven insight and proactive support to improve the chronic, comorbid patient experience.
Search jobs 10-Jan-2021 Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19
BURLINGAME, Calif. & CHICAGO (BUSINESS WIRE) Humanigen, Inc. (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, and EVERSANA, a pioneer of next-generation services to the global life sciences industry, today announced that they are partnering to make lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration (FDA) and subsequent BLA.
News Category Global Banking & Finance Reviews
Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19
Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19
Humanigen, Inc. (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab„¢, and EVERSANA, a pioneer of next-generation services to the global life sciences industry, today announced that they are partnering to make lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration (FDA) and subsequent BLA.